Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.
Annovis Bio, Inc. develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. News about ANVS commonly centers on clinical development of buntanetap, peer-reviewed publications, biomarker data, safety findings, and scientific presentations related to the company’s multi-protein approach to neurodegeneration.
Recurring updates also cover intellectual-property protection for buntanetap and related compounds, collaborations that add digital biomarker technology to Parkinson’s disease research, corporate financing, annual financial results, and other public-company developments tied to funding, governance, and clinical-regulatory disclosure.
Annovis Bio (NYSE: ANVS) announced it has regained compliance with NYSE continued listing standards. The NYSE had notified the company on March 26, 2025 that its average global market cap and stockholders' equity were each below $50 million.
After NYSE accepted an 18‑month cure plan on June 19, 2025, Annovis executed corrective actions that raised both metrics above required thresholds within 12 months. NYSE has confirmed full compliance, and ANVS shares will remain listed as the company focuses on pivotal Phase 3 Alzheimer’s data and regulatory submissions.
Annovis (NYSE: ANVS) priced an underwritten public offering of 7,895,000 common shares and accompanying warrants to purchase up to 7,105,500 shares at a combined price of $1.90 per share and warrant.
Gross proceeds are expected to be about $15.0 million, mainly funding buntanetap Phase 3 programs in AD and PD.
Annovis (NYSE: ANVS) launched a proposed underwritten public offering of common stock and accompanying warrants, which must be purchased together. All securities are offered by the company, with Canaccord Genuity as sole bookrunner.
Net proceeds are expected to fund Phase 3 development of buntanetap for Alzheimer’s disease, plus working capital and general corporate purposes. The offering’s completion, size and terms remain subject to market and other conditions.
Annovis (NYSE: ANVS) reported first quarter 2026 updates on buntanetap for Alzheimer's and Parkinson's and its financial position.
The Phase 3 AD trial is 85% enrolled with positive 6‑month DSMB safety review, the PD OLE study is 40% enrolled, key publications and a new U.S. patent were issued, and cash totaled $14.2 million at March 31, 2026.
Annovis (NYSE: ANVS) announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13, 2026 (1:40–2:05 PM, Picasso 4&5).
The talk covers a multi-protein model of Alzheimer’s disease, arguing for targeting amyloid, tau, alpha-synuclein, TDP-43 and other aggregating proteins. The presentation includes a Q&A and highlights Annovis’ lead oral drug, buntanetap, now in a pivotal Phase 3 trial.
Annovis (NYSE: ANVS) published Phase 2/3 results for oral buntanetap in Nature NPJ Dementia showing dose-dependent cognitive improvement in pTau217-positive mild AD patients and biomarker reductions. The randomized 12-week trial (351 patients) found buntanetap safe and well-tolerated, including in ApoE4 carriers. The company is advancing a pivotal Phase 3 in early AD (MMSE 20–28), now ~80% enrolled.
Biomarker changes included lower TDP-43, tau, NfL and reduced inflammatory markers, supporting potential disease-modifying activity; Phase 3 will evaluate effects at 6 and 18 months.
Annovis Bio (NYSE: ANVS) closed an underwritten public offering raising approximately $10 million, plus a $1.5 million board investment, extending cash runway through Q2 2027 to fund a key 6‑month Phase 3 Alzheimer's symptomatic readout and an ensuing NDA submission.
The Phase 3 AD trial is ~75% enrolled; FDA agreed to integrate safety data from AD and PD trials into the AD NDA. An open‑label Parkinson's study is 28% enrolled and includes an AI digital biomarker device for real‑time monitoring.
Annovis (NYSE: ANVS)/b) priced an underwritten offering of of common stock with accompanying warrants at a combined price of $1.90 per share/warrant, expected to raise approximately $10 million in gross proceeds before fees.
Each warrant is exercisable for one share at $2.50, becomes exercisable six months after issuance, and expires five years and six months after issuance. Closing is expected on or about April 10, 2026. Net proceeds will fund Phase 3 development of buntanetap and general corporate purposes.
Annovis (NYSE: ANVS) announced issuance of U.S. Patent No. 12,582,632 B2 for buntanetap covering prevention and treatment of neurological injuries caused by brain infections. The patent covers administration across viral, bacterial, fungal, protozoan and parasitic agents, includes preventive and reversal claims, and extends through 2044.
The company is a Phase 3 clinical-stage developer of buntanetap for neurodegenerative diseases.
Annovis (NYSE: ANVS) announced publication of a historical review of its lead candidate buntanetap in The Scientist on March 31, 2026. The article traces buntanetap's discovery, chemical refinement and clinical progress, and places its development in scientific and historical context.
Clinical status: pivotal Phase 3 in early AD (NCT06709014) is 70% enrolled; PD open‑label extension (NCT07284784) is 20% enrolled.